| abstract |
The present invention relates to a HDM2-p53 interaction inhibitor (S)-5-(5-chloro-1-methyl-2-oxo-1,2-dihydro-pyridin-3-yl)-6 for use in the treatment of hematologic tumors -(4-Chloro-phenyl)-2-(2,4-dimethoxy-pyrimidin-5-yl)-1-isopropyl-5,6-dihydro-1H-pyrrolo[3,4-d] Imidazol-4-one (HDM201), wherein the drug is administered according to an extended low-dose regimen characterized by a higher dose during induction and a lower dose during intensification. |